29
Mar
2020
COVID-19 Teaches Us the Real Definition of a ‘Novel’ Drug
Will the world care how we beat COVID-19 – whether with a drug we make from scratch or an older one that turns out to get the job done? As people concerned for our families, we all know the answer. Just get it done! But as drug developers, let’s be honest that it doesn’t feel quite as heroic unless it’s... Read More
28
Mar
2020
Knowledge is Power: Don’t Give Up on Diagnostic Tests for COVID19
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Mar
2020
The Seattle Scientific Community, Mobilized
“When I was a boy and I would see scary things in the news, my mother would say to me, ‘Look for the helpers. You will always find people who are helping.’” – Fred Rogers The Seattle scientific community has always been tight-knit and collaborative, but we have mobilized like never before to respond to the threat of COVID-19. My... Read More
27
Mar
2020
Do’s and Don’ts of Staying Connected in the Time of Physical Distancing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Mar
2020
Singapore: Braving the Second Wave of COVID19
A week ago, I wrote an article for Timmerman Report on Singapore’s COVID19 response, and how the country has kept its cases low with no COVID19-related deaths. In that article on Mar. 19, I elaborated on how Singapore had not ordered any businesses to shut down. Instead, the country had kept the number of cases low over the last few... Read More
26
Mar
2020
Adjusting to Telemedicine: A First-Hand Account
One consequence of the present crisis is the urgent embrace of telemedicine, as I recently discussed. Whether the adoption is sustained beyond the crisis period remains to be determined, although use seemed to be increasing overall even before the pandemic hit. As more physicians and patients find themselves pressed to adopt telemedicine, I thought it might be helpful to better... Read More
26
Mar
2020
The Coronavirus Tsunami, Lyell’s $492M Megaround & Some Deals You Missed
When a story moves with exponential speed and deadly force, it’s hard for a human being to keep up. Hard for you, and hard for me. My approach these past few weeks has been to work with purpose and passion on this story that touches all of humanity. The plan has been to seek out diverse voices with fresh perspectives... Read More
26
Mar
2020
Pharmacy as the Biomarker of Biopharma’s Strategic Change, After Coronavirus
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Mar
2020
We Interrupt This Nightmare to Bring You a Few Giggles
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Mar
2020
Unsung Heroes Who Give Me Hope
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Mar
2020
A Surge of Gratitude, From a Doctor on the Front Lines of COVID-19 in Boston
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Mar
2020
What Not To Do: Lessons From Spain’s Cavalier Response to COVID-19
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Mar
2020
Doctor, Mother, CEO: Balancing Competing Needs, and Opting for the Front Lines
Yesterday I woke up on an island. I am temporarily – but purposefully — isolating myself and my two children, ages 10 and 12, in a familiar place that carries with it a slower rhythm from a different time. It’s our second home. It also happens that, on the first day of spring, there are still no cases of suspected... Read More
24
Mar
2020
Digital Tools in Clinical Trials Find Opportunity During Pandemic
The current crisis represents a potentially defining moment for at least some health technologies and technology-enabled services. Telehealth, as discussed in my last column, is one conspicuous example, and the jury is still out. The potential benefit seems especially striking at a time when so many Americans are being told to stay at home, yet there are also serious concerns,... Read More
23
Mar
2020
New Drugs at Low Prices: Alexis Borisy and Melanie Nallicheri of EQRx on The Long Run
Today’s guests on The Long Run are Alexis Borisy and Melanie Nallicheri. Alexis is the chairman and CEO of EQRx, and Melanie is the president and chief operating officer. EQRx is a startup in Cambridge, Massachusetts. It aspires to develop new medicines for serious diseases like cancer. That’s nothing unusual. What is unusual is that EQRx is seeking to create... Read More
23
Mar
2020
Let it Rip or Shelter at Home? Choosing Between Two Bad Options on Coronavirus
Like most of you, I have been obsessively following “the virus.” It is having a devastating impact on human life, hospital systems, governments and economies. The worst is still to come, based on what we know about this new coronavirus and its ability to spread with exponential force. Here are some thoughts on the difficult choices laying ahead. Before I... Read More
23
Mar
2020
Staying Mentally Healthy to Weather the COVID19 Crisis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Mar
2020
Why Telehealth Champions Are Worried About Trust
Crises can serve as catalysts. History has shown they increase the recognition that change is needed, and lower the activation energy required for it to occur. The COVID-19 crisis has already been widely recognized as potential catalyst for telemedicine, and more generally for the accelerated adoption of digital tools in both clinical medicine and clinical trials. In just the last... Read More
21
Mar
2020
Love in the Time of Coronavirus
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Mar
2020
In Times of Coronavirus Pandemic, it Takes a Global Village
For some US biotech companies today, the ability to maintain business and societal continuity during the COVID–19 pandemic comes with assistance from a surprising source. Contract research organizations (CROs) based in China were the first – and most severely — impacted by the new coronavirus outbreak in January. But they are now rebounding to provide their traditional services to biopharma... Read More